COVID-19 Causes 67% of Experts to use Decentralized Trials in Future, says GlobalData

September 1, 2020

Healthcare experts have noted that their number one primary concern amid the COVID-19 pandemic was the delay to initiation or inability to conduct clinical trials, according to a recent survey by GlobalData. The data and analytics company notes that at peak over 1,200 clinical trials experienced some level of delay due to the COVID-19 pandemic.

The survey, completed between June 4th-22th, found remote patient monitoring and shifting towards the use of decentralized clinical trials were the top two methods respondents are using to address disruptions. Out of 150 respondents, only 34% were already using decentralized clinical trials, most located in North America. Contract service providers were the biggest current adopters.

Furthermore, according to 67% of survey participants, COVID-19 is the reason they plan to use decentralized clinical trials in the future.

Read the full release and get more of the findings, here.

Related Content:

News